Zobrazeno 1 - 10
of 155
pro vyhledávání: '"Jian-Guo Sun"'
Autor:
Shu‐ting Lin, Hong‐jiang Li, Yi‐zhong Li, Qian‐qian Chen, Jia‐yi Ye, Shu Lin, Si‐qing Cai, Jian‐guo Sun
Publikováno v:
Cancer Medicine, Vol 13, Iss 8, Pp n/a-n/a (2024)
Abstract Purpose Contrast‐enhanced spectral imaging (CEM) is a new mammography technique, but its diagnostic value in dense breasts is still inconclusive. We did a systematic review and meta‐analysis of studies evaluating the diagnostic performan
Externí odkaz:
https://doaj.org/article/ef31084b68274f459daa81a4295d08a3
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Immune checkpoint inhibitors (ICIs) have revealed significant clinical values in different solid tumors and hematological malignancy, changing the landscape for the treatment of multiple types of cancer. However, only a subpopulation of patients has
Externí odkaz:
https://doaj.org/article/e2299340d91743bcbe19a65000c8381c
Autor:
Ling-Chen Li, Xie-Wan Chen, Ling Fang, Chun-Li Jian, Yong-Xin Yu, Xing-Yun Liao, Jian-Guo Sun
Publikováno v:
Canadian Respiratory Journal, Vol 2023 (2023)
Background. Immune checkpoint inhibitors (ICIs) have become a standard care in non-small-cell lung cancer (NSCLC). However, its application to epidermal growth factor receptor (EGFR)-mutant NSCLC patients is confronted with drug resistance. This stud
Externí odkaz:
https://doaj.org/article/cefbf99075a74e289026c7edcddeb7a7
Autor:
Hong-can Ren, Jian-guo Sun, Ji-ye A, Sheng-hua Gu, Jian Shi, Feng Shao, Hua Ai, Jing-wei Zhang, Ying Peng, Bei Yan, Qing Huang, Lin-sheng Liu, Yang Sai, Guang-ji Wang, Cheng-guang Yang
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
Aim: The 20(S)-ginsenoside Rh2 (Rh2) is being developed as a new antitumor drug. However, to date, little is known about the kinetics of its deglycosylation metabolite (protopanoxadiol) (PPD) following Rh2 administration. The aim of this work was to
Externí odkaz:
https://doaj.org/article/017a3354f1f2423aa37dd4a95ea709e4
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
MicroRNA (miR)-1246 is abnormally expressed and has pro-oncogenic functions in multiple types of cancer. In the present study, its functions in breast cancer and the underlying mechanisms were further elucidated. The clinical relevance of miR-1246 wa
Externí odkaz:
https://doaj.org/article/00d0608b71ad4e178d6f10bd52449bb2
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The resistance to radiotherapy in lung cancer can be attributed to vasculogenic mimicry (VM) to some extent. Celecoxib (CXB), a selective inhibitor of cyclooxygenase-2 (COX-2), is reported as a radiosensitizer in non-small cell lung cancer (NSCLC). H
Externí odkaz:
https://doaj.org/article/0289538aad104f4bae9044388c447166
Cyclosporine A-loaded drug delivery systems inhibit scar formation after glaucoma surgery in rabbits
Publikováno v:
Chinese Medical Journal, Vol 132, Iss 11, Pp 1381-1384 (2019)
Externí odkaz:
https://doaj.org/article/bfb9a64f10f742898c7a42a169de92ed
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-4 (2018)
Abstract Background Among non-small cell lung cancer (NSCLC) patients with acquired T790 M mutation resistance to first-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), 71% are likely to benefit from osimertinib. Ther
Externí odkaz:
https://doaj.org/article/36e6aedfb67a4d2b84da9b1441257ad7
Autor:
Hai-Zhen Zhu, Jing Hou, Yi Guo, Xin Liu, Fei-Long Jiang, Guang-Peng Chen, Xiu-Feng Pang, Jian-Guo Sun, Zheng-Tang Chen
Publikováno v:
Drug Delivery, Vol 25, Iss 1, Pp 1974-1983 (2018)
Lung cancer is still the most common cancer globally. Early screening remains the key to improve the prognosis of patients. There is currently a lack of specific and sensitive methods for early screening of lung cancer. In recent years, studies have
Externí odkaz:
https://doaj.org/article/40e1957ed8ca45beaedab30c8236287f
Publikováno v:
Tongxin xuebao, Vol 38, Pp 140-148 (2017)
A method of improved support vector machine naive Bayes algorithm was proposed——TSVM-NB algorithm.
Externí odkaz:
https://doaj.org/article/964ed875e00a4b98ad724f733935bf56